6,678 trials
Systemic Lupus Erythematosus (SLE)
Primary: Number of Participants Who Meet the Definition of a Responder Within 4 Weeks — 3; 4 Participants
Renal Failure
Primary: Number of Participants With Undetectable HCV RNA at SVR12 — 8 Participants
Hypertension
Primary: Trough Seated Diastolic Blood Pressure — -9.4; -5.0 mm Hg
Hip Fractures
Primary: Opiate Requirements — 52.5; 65.39 Morphine mEq
Chronic Obstructive Pulmonary Disease · Asthma · Pneumococcal Infections
Primary: Number of Patients Without Exacerbations of the Underlying Disease, Antibiotic Use and Hospitalisation. — 3; 5; 1; 0 Participants — p=<0.05
Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Primary: Difference in Mean Number of Ranibizumab Injections — 4.3; 4.1 number of injections — p=0.3680
CHRONIC SPONTANEOUS URTICARIA
Primary: Percent of Participants With an Urticaria Control Test [UCT] Score of Greater Than or Equal to 12 — 75.0 percent of participants
Hyperopia · Myopia
Primary: Higher Order Aberrations — 0.001646; 0.002629 microns
Headache · Tumor · Seizure Disorder
Primary: Efficiency of Propofol Dexmedetomidine Sedation Compared With Propofol Infusion — 98; 77 minutes
Laparoscopic Surgery
Primary: Postoperative Pain — 3.2; 3; 3.9 Score on scale 0-10
Neuromuscular Blockade
Primary: Number of Hypoxic Episodes — 1; 0 episode(s)
Adherence, Medication · Risk Behavior · Pre-Exposure Prophylaxis
Primary: DOT Diary Mobile App Acceptability — 79.8 Score on scale
Respiratory Insufficiency
Primary: Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response) — 0.66; 0.43; 0.54; 0.34 L/min/% desaturation
Depression
Primary: Changes in Quantitative Electroencephalogram (qEEG) Prefrontal Cordance (PFC) Over Time (4 Weeks). — -0.54; -0.09; -0.09; -0.88 z-score — p=0.55
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale